Extracellular heat shock protein can deliver associated antigens into the MHC class I presentation pathway of antigen-presenting cells, a process called cross-presentation, thus inducing antigenspecific CD8
Introduction
Professional antigen-presenting cells (APCs), particularly dendritic cells (DCs), can take up exogenous antigens and present them on their MHC class I molecules. This process is referred to as cross-presentation and plays an important role in priming antigen-specific naive CD8
+ T-cell responses to tumor cells, virus-infected cells and transplants that cannot access the classical pathway for MHC class I presentation. Therefore, it is often considered in vaccination strategies aimed at improving CD8 + T-cell responses. However, the exact mechanism for introduction of exogenous antigen into cross-presentation pathway remains unclear. Recent evidence indicates that exogenous antigens can be processed through at least two distinct pathways, one involving access of exogenous antigens to the classical MHC class I loading pathway [transporter-associated antigen processing (TAP) dependent] and another involving unconventional post-Golgi loading of MHC class I molecules in endocytic compartments (TAP independent) (1). One or both of these pathways can contribute to cross-presentation depending on the source of the exogenous antigens such as soluble proteins, immune complexes or peptides chaperoned by heat shock proteins (HSPs).
HSPs are molecular chaperones that control the folding of proteins and prevent their aggregation. They are capable of interacting with a broad range of peptides within the cell and the resulting HSP-peptide complexes elicit CD8 + T-cell responses by cross-presentation (2) . Above all, Hsp70 and gp96 have been shown to elicit efficient CTL induction by cross-presentation and anti-tumor immune responses (3) (4) (5) (6) (7) (8) . In contrast, it has been less elucidated whether Hsp90 is involved in the cross-presentation. Udono and Srivastava (9) reported, for the first time, that immunization with Hsp90 purified from a tumor elicited tumor-specific CTL responses. Recently, Kunisawa and Shastri (10) reported that Hsp90 chaperoned C-terminal flanking antigenic peptides. Furthermore, Callahan et al. have demonstrated that endogenous Hsp90 binds N-terminal flanking precursor peptides within the cells and these peptides are cross-presented by APCs (11) . We also demonstrated that extracellular Hsp90-peptide complexes generated in vitro were efficiently crosspresented by DCs and recognized by peptide-specific CTLs. (12) . Taking these facts into consideration, it seems possible that Hsp90 is able to form highly immunogenic Hsp90-'protein antigen' complexes and to elicit antigen-specific CTL responses through cross-presentation. In this study, we therefore investigated the role of Hsp90 in the presentation of exogenous protein antigens using ovalbumin (OVA) as a surrogate antigen. We show that the Hsp90-OVA complex generated in vitro is efficiently and preferentially presented via the MHC class I pathway both in vitro and in vivo. Furthermore, our data suggest that extracellular Hsp90, at least in part, contributes to the translocation of chaperoned antigens from the endosomes into cytosol, resulting in proteasomal degradation. These results provide a rationale for the development of Hsp90-based vaccination strategies for cancer as well as viral immunity. ) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and used at 6 weeks of age. All animal experiments were approved by the Experimental Animal Committee of Sapporo Medical University. B3Z cell is an SL8 (SIINFEKL) peptide-specific CD8 + T-cell hybridoma that was stably transfected with the IL-2 promoter-lacZ construct. When B3Z cells recognized peptide SL8 in the context of H-2Kb, activated IL-2-lacZ was induced and its product, b-galactosidase activity, was assayed as the cleavage of substrate chlorophenol red-b-D-galactopyranoside (CPRG) by measuring the absorbance of the cleaved product at 595 nm. As it has been shown that this b-galactosidase activity parallels the conventional IL-2 response, we compared the cross-presentation efficiency by measurement of it. The cell lines were obtained from Dr N. Shastri (University of California at Berkeley, Berkeley, CA, USA) and cultured in RPMI-1640 medium (Nissui, Tokyo, Japan) with 10% FCS (Invitrogen, Carlsbad, CA). EL4, E.G7 (EL4 transfected with cDNA encoding OVA) and YAC-1 cells were obtained from American Type Culture Collection (Manassas, VA).
Materials and methods

Mice and cell lines
Generation of bone marrow-derived DCs
Bone marrow-derived immature DCs were generated from the femurs and tibiae of female B6C3F1 mice and TAP À/À mice. Subsequently, 1 3 10 4 bone marrow cells per well in a 24-well plate were incubated in complete RPMI-1640 with 10% FCS and 20 ng ml À1 granulocyte macrophage colony-stimulating factor (GM-CSF) (Endogen, Inc., Woburn, MA) for 5 days. Medium with GM-CSF was gently replaced on day 2 and day 4.
Peptides and proteins
All peptides were synthesized on a solid phase support using F-moc for transient NH 2 terminal protection and were characterized using mass spectrometry. All peptides used in this study were purified by HPLC to >99% homogeneity. The single-letter code sequences of the peptides used were as follows: H-2K b -restricted SL8, SIINFEKL (positions 257-264 of the OVA protein) and I-A k -restricted PL19, PDEVS-GLEQLESIINFEKL (positions 246-264 of the OVA protein). Chicken OVA was purchased from Calbiochem (La Jolla, CA), and stored at 20 mg ml À1 in PBS at À80°C. Human Hsp90 was purchased from StressGen Biotechnologies (Victoria, BC, Canada). Quantification of endotoxin in Hsp90 and OVA was performed using the endotoxin-specific chromogenic test (ES test; Seikagaku Kogyo, Tokyo, Japan). If the endotoxin level in the Hsp90 or OVA preparation was higher than the limit of detection (<5 pg ml À1 ), the endotoxin was depleted using Detoxi-Gel endotoxin removing gel (Pierce, Rockford, IL), after which the endotoxin was re-quantified.
Antibodies
Confocal laser microscopy was used to detect organelles with specific antibodies: an anti-Rab5 pAb (MBL, Nagoya, Japan) for early endosomes, anti-LAMP-1 pAb (Santa Cruz Biotechnology, Santa Cruz, CA) for late endosomes/lysosomes, antiRab11 pAb (Santa Cruz Biotechnology) for recycling endosomes, anti-KDEL mAb (StressGen Biotechnologies) for endoplasmic reticulum (ER) and anti-LMP2 pAb (Santa Cruz Biotechnology) for proteasomes. The antibodies were each conjugated with Alexa Fluor 488 (Molecular Probes, Eugene, OR) according to the manufacturer's instructions. Alexa Fluor 594 (Molecular Probes) was used for labeling with Hsp90 and OVA. A mouse anti-OVA mAb (Calbiochem), rabbit anti-OVA pAb (Sigma-Aldrich, St Louis, MO), rat anti-Hsp90 mAb (StressGen Biotechnologies), mouse anti-transferrin mAb (Sigma-Aldrich), mouse anti-Hsp72 mAb (StressGen Biotechnologies) and mouse anti-ß-Actin mAb (Sigma-Aldrich) were used in immunoblots. Rat IgG 2a (cloneR35-95) was purchased from BD Biosciensces (San Jose, CA).
Hsp90-protein binding
In vitro generation of the Hsp90-OVA complex was performed by the modified method described earlier (12) . Hsp90 (100 lg) and OVA (200 lg) were mixed and incubated for 10 min at 45°C. The samples were then incubated for 30 min at room temperature. Samples were injected onto a HiLoad 16/60 Superdex 200 gel filtration column (GE Healthcare Japan, Tokyo, Japan) at 0.2 ml min
À1
, and each of the fractions was analyzed by SDS-PAGE under reducing conditions; then the gels were stained for proteins using Comassie brilliant blue (Bio-Rad, Richmond, CA), followed by western blotting with the anti-Hsp90 mAb or anti-OVA mAb. To determine the binding stoichiometry of Hsp90 and OVA, protein intensities on the gel were quantified using Image-J software (NIH, Bethesda, MD). In some experiments, free Hsp90 and OVA protein were removed completely using a Microcon YM-100 (Millipore, Bedford, MA) and the purity of the Hsp90-OVA complex was examined by gel filtration and SDS-PAGE. To confirm whether Hsp90-OVA or OVA alone aggregated during incubation at 45°C for 10 min, followed by incubation at room temperature for 30 min, the solutions were centrifuged at 16 000 3 g for 15 min, and soluble and pellet fractions were separated, run on SDS-PAGE.
Immunoprecipitation
To confirm the generation of a complex between Hsp 90 or transferrin and OVA, the two proteins were combined at a 1:1 molar ratio and incubated for 10 min at the heat shock temperature of 45°C, followed by incubation at room temperature for 30 min. The complex was pretreated with 30 ml of protein G beads and immunoprecipitated using a mouse anti-human Hsp90 mAb, rabbit anti-OVA pAb or mouse antitransferrin mAb. After 10% SDS-PAGE, western blot analysis was done using the rabbit anti-OVA antibody.
Antigen presentation assay
Hsp90 (100 lg), OVA (100 lg) or Hsp90 (100 lg) mixed with OVA (100 lg) for the generation of a complex were incubated for 10 min at 45°C, followed by incubation for 30 min at room temperature. This treatment did not result in the formation of a protein aggregation, which was confirmed by the method described above. In dose titration assay, DCs (1 3 10 5 ) from B6C3F1 were loaded with various doses of OVA or Hsp90-OVA complex for 2 h at 37°C in 100 ll of Opti-MEM (Invitrogen), and fixed for 1 min with 0.01% glutaraldehyde (Sigma-Aldrich). Fixation was stopped by addition of 2 M L-lysine (Sigma-Aldrich) and the cells were washed two times with RPMI-1640 medium and cultured overnight with 1 3 10 5 B3Z. In antigen-presentation assay, DCs (1 3 10 5 ) from B6C3F1 and TAP À/À mice were pulsed with Hsp90 (20 lg) alone, OVA (20 lg) alone, a simple mixture of the two, a complex of them generated in vitro (without removal of free Hsp90 and OVA for loading the same amount of Hsp90 or OVA in cultures), SL8 (1 lM) or PL19 (1 lM) for 2 h at 37°C and fixed and then cultured overnight with 1 3 10 5 B3Z or KZO. Stimulated B3Z and KZO cells were stained with CPRG (purchased from Roche, Basel, Switzerland) and red color was measured as absorbance at 595 nm.
Inhibition assay
DCs (1 3 10 5 ) from B6C3F1 mice were pre-incubated with the following inhibitors: chloroquine (Sigma-Aldrich), primaquine (ICN Biomedicals Inc., Aurora, OH), cycloheximide (Sigma-Aldrich), MG-132 (Calbiochem) and leupeptin (Calbiochem). These inhibitors were not toxic in our culture systems. Two hours after pre-incubation, the DCs were pulsed with the Hsp90 (20 lg)-OVA (20 lg) complex or SL8 (1 lM) for 2 h at 37°C in 100 ll of Opti-MEM, and then fixed, washed and cultured overnight with B3Z. Stimulated B3Z cells were stained with CPRG and red color was measured as absorbance at 595 nm.
Immunocytological localization of Hsp90-OVA complex
DCs from B6C3F1 mice were incubated at 37°C with Alexa Fluor 594-labeled OVA (20 lg), Hsp90 (20 lg) complexed with Alexa Fluor 594-labeled OVA (20 lg) or Alexa Fluor 594-labeled Hsp90 (20 lg) complexed with OVA (20 lg) for 1 h. Following incubation, cells were washed twice with ice-cold PBS, and fixed with ice-cold acetone for 1 min. Organelles were stained with an anti-Rab5 pAb for early endosomes, anti-LAMP-1 pAb for late endosomes/lysosomes, anti-Rab11 pAb for recycling endosomes, anti-KDEL mAb for ER and anti-LMP2 pAb for proteasomes, conjugated with Alexa Fluor 488 and visualized with a Bio-Rad MRC1024ES confocal scanning laser microscope system (Bio-Rad).
Endogenous Hsp90 inhibition assay
DCs (1 3 10 5 ) from B6C3F1 mice were pre-incubated with radicicol (Calbiochem). Two hours after pre-incubation with increased doses (1-5 lM) of radicicol, the DCs were pulsed with Hsp90 (20 lg)-OVA (20 lg), OVA (20 mg) or SL8 (1 lM) for 1 h at 37°C in 100 ll of Opti-MEM, and then fixed, washed and cultured overnight with B3Z. Stimulated B3Z cells were stained with CPRG and red color was measured as absorbance at 595 nm. For detecting localization of Hsp90-OVA complex, DCs were pre-incubated with radicicol at 5 lM. Two hours after pre-incubation, DCs were incubated at 37°C with Hsp90-Alexa Fluor 488-labeled-OVA complex (200 lg ml À1 ) for 1 h and then washed and fixed. Organelles were stained with an anti-LMP2 pAb conjugated with Alexa Fluor 594 and visualized with confocal laser microscopy. To verify the effect of radicicol, following treatment of DCs with the indicated concentrations of radicicol for 2 h, the cells were further cultured for 24 h, and cell lysates then were harvested. The expression of Hsp72 was determined by western blotting with an anti-Hsp72 mAb. The b-actin level was used as a loading control.
Transduction of anti-Hsp90 antibody for blocking the Hsp90 activity within the cytosol A rat anti-Hsp90 mAb was delivered into DCs from B6C3F1 mice using the BioPORTER protein delivery reagent (Gene Therapy Systems, San Diego, CA) according to the instructions of the manufacturer. The BioPORTER reagent forms a non-covalent complex with the antibody of interest, creating a protective vehicle for immediate delivery into cells. The hydrated mixture is added onto cells, and the Bio-PORTER/antibody complexes are endocytosed by the cells and then fuse with the endosome, leading to release of the BioPORTER-captured antibody into cytoplasm. One microgram of an anti-Hsp90 mAb or rat IgG 2a control protein was mixed with the BioPORTER protein delivery reagent and added to each dish of DCs (1 3 10 5 ). After incubation for 4 h, the medium was removed and the cells were washed with RPMI twice to remove any anti-Hsp90 mAb that did not enter the cells. The cells were incubated in the presence of the Hsp90 (20 lg)-OVA (20 lg) complex or SL8 (1 lM) for 2 h in 100 ll of Opti-MEM with pre-incubation of leupeptin (200 lM), and then fixed, washed and cultured overnight with B3Z. Stimulated B3Z cells were stained with CPRG and red color was measured as absorbance at 595 nm. At the same time, localization of internalized OVA in DCs was investigated in the presence of the anti-Hsp90 mAb by confocal laser microscopy. In addition, to examine the localization of Extracellular Hsp90 translocates Ag into cytosol 225 the transduced antibody, FITC-labeled goat IgG was added to DC culture. Organelles were then stained with an antiRab5 pAb for early endosomes conjugated with Alexa Fluor 594 and visualized with confocal laser microscopy.
In vivo cross-presentation assay B6C3F1 mice were immunized in their footpads with Hsp90 (50 lg) alone or OVA (50 lg) alone or an Hsp90 (50 lg)-OVA (50 lg) complex. Draining popliteal lymph nodes were removed after 4 h, and CD11c + DCs were purified using CD11c MACS beads (Miltenyi Biotec, Auburn, CA). Purified DCs were plated at a density of 10 3 in 10% RPMI 1640 and co-cultured overnight with 1 3 10 5 B3Z or KZO. Stimulated B3Z and KZO cells were stained with CPRG and red color was measured as absorbance at 595 nm.
Induction of CTL
C57BL/6 mice were immunized s.c. with the Hsp90 (50 lg)-OVA (50 lg) complex, Hsp90 (50 lg) or OVA (50 lg) on days 0 and 7. Mice were sacrificed for analysis of CTL responses against the SL8 peptide. Splenocytes from immunized mice were cultured in the presence of 1 lg ml À1 SL8 peptide at 5 3 10 6 cells ml À1 for 5 days. On day 5, cells were harvested for standard 4-h chromium release assay.
Tumor rejection experiments C57BL/6 mice were injected s.c. on days 0 and 7 with Hsp90 (50 lg)-OVA (50 lg), Hsp90 (50 lg) or OVA (50 lg). Seven days after the second immunization, mice were challenged i.d. with 1 3 10 5 E.G7 cells. Tumor size was measured in two dimensions twice a week. When mean tumor growth exceeded 20 mm in diameter, the mice were euthanized. Average tumor diameters on day 25 were statistically analyzed using the Mann-Whitney U test. Statistical analyses for evaluating the survival advantages on day 60 were performed using log-rank analysis. All the experiments were performed with 10 mice per group.
Statistical analysis
All experiments except for the tumor transplantation experiments were independently performed three times in triplicate. Results were given as means 6 SD. Comparisons between two groups were performed using Student's t-test, with a P value of <0.05 considered to be statistically significant.
Results
In vitro generation of Hsp90 and OVA protein complex
To critically evaluate the capacity of Hsp90 to elicit immune responses, we carefully removed endotoxins that would activate innate immune responses. As we and others have already demonstrated, heat shock treatment accelerates the loading of antigens onto the binding sites of Hsp90 and other HSPs (12) . Therefore, to generate the Hsp90-OVA complex in vitro, Hsp90 and OVA were mixed and incubated for 10 min at 45°C, followed by incubation for 30 min at room temperature. The resultant Hsp90-OVA complex was separated using gel filtration and each of the fractions was analyzed by SDS-PAGE. As shown in Fig. 1A , the typical pattern of elution using gel filtration for the samples presented three major peaks, and subsequent analyses by SDS-PAGE and western blotting identified the first one as the Hsp90-OVA complex, the second one as Hsp90 and the third one as OVA ( Fig. 1B and C) . Stoichiometric analysis using Image J software showed that the molar ratio of bound OVA to Hsp90 was ;2.0-2.2 mole OVA per mole of Hsp90. We carried out further experiments for the demonstration of the Hsp90-OVA complex. We performed co-immunoprecipitation assay using an anti-Hsp90 antibody and anti-OVA antibody. When the Hsp90-OVA complex was immunoprecipitated by the anti-Hsp90 antibody, we could detect OVA protein in the immunoprecipitates. Moreover, we performed crisscross immunoprecipitation assay using the anti-OVA antibody. We could also find Hsp90 in the immunoprecipitates. In contrast, when transferrin, as control protein, and OVA were incubated at 45°C for 10 min, followed by 30-min incubation at room temperature, we could not detect OVA in the immunoprecipitates made with an anti-transferrin antibody. These data suggested that Hsp90, but not transferrin, had the ability to generate a complex with OVA ( Fig. 2A and B) . To examine whether heat shock treatment caused aggregation, a mixture of Hsp90 and OVA or OVA alone was heated at 45°C for 10 min, followed by 30-min incubation at room temperature, and then centrifuged. Both the Hsp90-OVA complex and OVA were found in the soluble fractions, but not in the pellet (insoluble) fractions (Fig. 2C ). These data indicated that the Hsp90-OVA complex and OVA remained soluble and did not form aggregations resulting from the heat shock treatment.
OVA is efficiently cross-presented when complexed with Hsp90 by DCs
We evaluated the cross-presentation of the in vitro generated Hsp90-OVA complex. To begin with, we examined the cross-presentation efficacy of exogenous OVA by DCs. As shown in Fig. 3A , the cross-presentation efficacy of OVA was considerably low even if we loaded 200 mg ml À1 of OVA onto DCs. In contrast, OVA was efficiently crosspresented when complexed with Hsp90 (Fig. 3B) . We observed that the complex generated using 200 lg ml À1 Hsp90 and 200 lg ml À1 OVA yielded a >1000-fold increase in efficacy of the cross-presentation. Moreover, the stoichiometric analysis showed that 200 lg ml À1 Hsp90 could be complexed with 200 lg ml À1 OVA as described earlier. Additionally, we examined whether complex formation between Hsp90 and OVA was required for enhanced crosspresentation. DCs were pulsed with Hsp90 alone (200 lg ml À1 ), OVA alone (200 lg ml À1 ), a simple mixture of the two or a complex of them generated in vitro (without removal of free Hsp90 and OVA protein) for 2 h at 37°C, and then fixed, washed and cultured with B3Z T-cell hybridoma. DCs coated with peptide SL8 served as a positive control. The Hsp90-OVA complex elicited strong B3Z responses, whereas Hsp90 or OVA alone did not induce a B3Z response (Fig. 4A) . Notably, when we pulsed the simple mixture of Hsp90 and OVA, we did not detect a significant B3Z response. These results showed that binding to Hsp90 was essential for cross-presentation of OVA.
Hsp90-OVA complex is efficiently and preferentially presented through MHC class I pathway
We also tested whether the Hsp90-OVA complex was presented through the MHC class II pathway, and elicited CD4 + T-cell responses. According to stoichiometric analysis, as Hsp90 binds an equal amount of OVA almost completely (i.e. no free OVA protein in the culture), DCs from B6C3F1 were pulsed with OVA alone (200 lg ml À1 ) or Hsp90 (200 lg ml À1 )-OVA (200 lg ml À1 ), for 2 h at 37°C, and then fixed, washed and co-cultured with KZO CD4 + T-cell hybridoma. DCs coated with PL19 peptide served as a positive control. As expected, stimulation with soluble OVA induced a strong CD4 + T-cell response (Fig. 4B) . In contrast, stimulation with the Hsp90-OVA complex elicited a significantly weaker CD4 + T-cell response than soluble OVA. These findings suggested that the Hsp90-OVA complex was presented much more preferentially through the MHC class I pathway than the MHC class II pathway.
To examine the differences in presentation efficacy between Hsp90-OVA and free OVA, a pulse-chase experiment was performed. DCs were pulsed with OVA alone or Hsp90-OVA at 37°C, harvested at different time points between 10 min and 2 h and then fixed, washed and cultured with B3Z or KZO. B3Z responses were seen after 10-30 min of stimulation with Hsp90-OVA (Fig. 4C) , although no KZO response was detected up to 1 h with OVA alone (Fig. 4D) . These data demonstrated that processing and presentation of the Hsp90-OVA complex was more rapid and efficient than presentation of OVA alone. Hsp90, but not transferrin, is able to bind and inhibit aggregation of client protein at heat shock temperature. (A) Direct binding of Hsp90 and OVA protein is shown by immunoprecipitation using an Hsp90 antibody and OVA antibody, followed by western blotting using the Hsp90 antibody or OVA antibody. Transferrin was used as a control protein of with a molecular weight almost the same as that of Hsp90. (B) OVA was heated to 45°C for 10 min with or without Hsp90. The total reaction mixture was centrifuged at 16 000 3 g for 15 min to separate the supernatant and pellet. These fractions were separated and run on SDS-PAGE.
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Vacuolar acidification is required for cross-presentation of Hsp90-OVA complex After internalization by DCs, Hsp90-OVA possibly enters acidic endocytic compartments. To assess if inhibition of vacuolar acidification blocked cross-presentation of the Hsp90-OVA complex, we used chloroquine. DCs were pre-incubated with increasing concentrations of chloroquine, and then pulsed with Hsp90-OVA. Chloroquine completely blocked cross-presentation at 200 lM but had no substantial effect on SL8 presentation (Fig. 4E) . This showed that cross-presentation of Hsp90-OVA depended on vacuolar acidification, possibly including proteolysis by endosomal proteases. Moreover, as the Hsp90-OVA complex is expected to be taken up by receptor-dependent endocytosis, the acidic condition might be necessary to dissociate the Hsp90-OVA complex from such putative receptors.
Hsp90-OVA complex is cross-presented by both TAPdependent and TAP-independent pathways
It is generally accepted that exogenous antigens are crosspresented by two distinct pathways in TAP-dependent and TAP-independent fashions. We examined whether crosspresentation of Hsp90-OVA depended on TAP transport. DCs from B6C3F1 or TAP À/À mice were pulsed with Hsp90-OVA for 2 h. Cross-presentation of the Hsp90-OVA complex by TAP-deficient DCs dropped 40-50% compared with that by B6C3F1 WT-derived DCs, whereas SL8 presentation was not affected (Fig. 5A) . This indicated that Hsp90-OVA was cross-presented via both TAP-dependent and TAP-independent pathways. Antigenic peptides are considered to be loaded in a TAP-dependent manner onto newly synthesized MHC class I molecules in ER and in a TAP-independent manner onto recycling MHC class I molecules in endocytic compartments. To evaluate these processes in our system, we used cycloheximide, an inhibitor of protein synthesis, and primaquine, an inhibitor of membrane recycling. DCs were pre-incubated with cycloheximide or primaquine and subsequently pulsed with Hsp90-OVA. Both inhibitors decreased cross-presentation of the complex dose-dependently ( Fig. 5B  and C) . These data suggested that cross-presentation of Hsp90-OVA accessed both newly synthesized MHC class I molecules in ER and recycling MHC class I molecules in endocytic compartments.
Both proteasomal processing and proteolysis by cysteine/ serine proteases are involved in cross-presentation of Hsp90-OVA complex
Proteins are degraded by proteasomes into shorter peptides via the TAP-dependent pathway of cross-presentation. To test whether proteasomal enzymes were involved in crosspresentation of Hsp90-OVA, we used MG-132, a potent proteasome inhibitor. MG-132 partially blocked cross-presentation of the complex but had no substantial effect on SL8 presentation (Fig. 5D) . Therefore, proteasomal proteolysis is required for the TAP-dependent pathway of the Hsp90-OVA complex.
A recent report indicated that the TAP-independent pathway of cross-presentation depended on cysteine/serine proteases in endocytic compartments. We tested the effect of treating DCs with leupeptin, an inhibitor of cysteine and serine proteases. Leupeptin partially inhibited the DC cross-presentation capacity of the Hsp90-OVA complex (Fig. 5E ). As expectedly, presentation of soluble OVA by MHC class II was completely inhibited by leupeptin pretreatment (Fig. 5F ). Notably, cross-presentation of Hsp90-OVA was further inhibited by treatment with a combination ) or SL8 (1 lM) for 2 h at 37°C, and then fixed, washed and cultured overnight with B3Z. The B3Z response was measured as b-galactosidase activity using CPRG by the absorbance at 595 nm. SL8 served as a positive control. (B) DCs were pulsed with Hsp90 alone, OVA alone, Hsp90-OVA or PL19 (1 lM) for 2 h at 37°C, and then fixed, washed and cultured overnight with KZO. PL19 served as a positive control. (C and D) DCs were pulsed with OVA alone or Hsp90-OVA at 37°C, harvested at different time points between 10 min and 2 h, and then fixed, washed and cultured overnight with B3Z (C) or KZO (D). (E) DCs were pre-incubated with chloroquine at 37°C for 2 h, and then pulsed with Hsp90-OVA or SL8 for 2 h. The DCs were then fixed, washed and cultured overnight with B3Z. Data are shown as means 6 SD of three independent experiments. *, P < 0.01.
of MG-132 (30 lM) and leupeptin (50 lM) (Fig. 5G) . These findings indicated that Hsp90-OVA was cross-presented by two distinct proteolytic pathways, one involving proteasomes and the other involving endocytic compartments.
Exogenous OVA and Hsp90-OVA complex show different subcellular localization after uptake by DCs
To further support all of the above results, we investigated the fate of Hsp90-OVA after its uptake in DCs, using confocal laser microscopy. DCs were incubated with Alexa 594-labeled soluble OVA or the Hsp90-Alexa 594-labeled-OVA complex for 1 h. Following incubation, the cells were fixed and stained with antibodies against markers for organelle structures such as Rab5, LAMP-1, Rab11, KDEL and LMP-2. Soluble OVA was detected in early endosomes to lysosomes, but not in recycling endosomes, ER or proteasomes (Fig. 6A) . On the other hand, Hsp90-chaperoned Alexa 594-labeled OVA was observed to co-localize with ), Hsp90-OVA or SL8 (1 lM) for 2 h at 37°C. The DCs were then fixed, washed and cultured overnight with B3Z. The B3Z response was measured as b-galactosidase activity using CPRG by the absorbance at 595 nm. SL8 served as a positive control. (B and C) DCs were pre-incubated with cycloheximide (B) or primaquine (C) at 37°C for 2 h, and then pulsed with Hsp90-OVA or SL8 for 2 h. The DCs were then fixed, washed and cultured overnight with B3Z. The B3Z response was measured by the absorbance at 595 nm. (D-G) DCs were pre-incubated with MG-132 (D), leupeptin (E and F) or both of them (G) at 37°C for 2 h, and then pulsed with Hsp90-OVA, SL8 or OVA for 2 h. The DCs were then fixed, washed and cultured overnight with B3Z or KZO. The B3Z or KZO response was measured by the absorbance at 595 nm. Data are shown as means 6 SD of three independent experiments. *, P < 0.01. early endosomes, recycling endosomes and proteasomes, but not in lysosomes or ER (Fig. 6B) . To confirm whether exogenous Hsp90 also co-localized with cytosolic proteasome, DCs were incubated with Alexa 594-labeled Hsp90 complexed with OVA. We observed that the exogenous Hsp90 was detected in early endosomes and proteasome subunit LMP-2, but not in lysosomes and recycling endosomes (Fig.   7 ). These data demonstrated that the part of exogenous Hsp90-OVA complex translocated from early endosomes into the cytosol while it has been unclear whether the Hsp90 and OVA remain in the complex or not, followed by association with proteasomes. Moreover, unlike in the data from localization of Hsp90-Alexa 594-labeled OVA, Alexa 594-labeled Hsp90 did not co-localize with recycling endosomes, suggesting that a part of OVA chaperoned by Hsp90 was released from Hsp90 within early endosomes, followed by translocation to recycling endosomes where recycling MHC class I molecules existed.
Inhibition of endogenous Hsp90 does not affect the crosspresentation of exogenous Hsp90-OVA complex
Recently, it has been demonstrated that endogenous cytosolic Hsp90 plays an important role in antigen presentation of exogenous as well as endogenous antigens. To investigate whether endogenous Hsp90 was responsible for the crosspresentation of the exogenous Hsp90-OVA complex, we treated DCs with the Hsp90-specific inhibitor radicicol in a cross-presentation assay. The results showed that treatment of DCs with radicicol did not affect the cross-presentation of exogenous Hsp90-OVA, suggesting that endogenous Hsp90 might not responsible for the exogenous Hsp90-mediated cross-presentation (Fig. 8A) . Moreover, radicicol treatment did not affect the co-localization of the internalized Hsp90-chaperoned OVA and LMP2 (Fig. 8B) . In contrast, high concentration of soluble OVA (200 mg ml
À1
) was cross-presented by DCs, although it was considerably less efficiently than Hsp90-OVA complex. Interestingly, this cross-presentation was radicicol sensitive, indicating that endogenous Hsp90 played a very important role in the cross-presentation of exogenous OVA (Fig. 8C) . However, as it is not clear how endogenous Hsp90 participates in the cross-presentation, we are currently studying the possibility that endocytosed soluble OVA might be translocated by endogenous Hsp90 into the cytosol for proteasomal degradation. It has been demonstrated that treatment with radicicol induces stress responses such as induction of Hsp72 protein. Therefore, we examined whether the concentration of radicicol used in our experiments was effective to induce Hsp72 expression. When DCs were exposed to the radicicol at concentrations of 1.0 lM and 5.0 lM for 2 h, the expression of Hsp72 was clearly induced compared with control cells (Fig. 8D) , indicating that concentration of radicicol used in the cross-presentation assay was sufficient enough for the inhibition of Hsp90 function of DCs. Thus, collectively, exogenous Hsp90, but not endogenous Hsp90, might be required for cross-presentation of exogenous antigens chaperoned by Hsp90.
Exogenous Hsp90 contributes to the translocation of chaperoned OVA to proteasomes
We hypothesized that exogenous Hsp90 itself was responsible for the efficient translocation of chaperoned OVA to the site for proteasomal degradation. To test this idea, we introduced an anti-Hsp90 antibody into the cytosol of DCs to inhibit the activities of both endogenous Hsp90 and exogenous Hsp90. We utilized the BioPORTER protein delivery reagent to introduce the anti-Hsp90 mAb into DCs. The Bio-PORTER/antibody complexes are endocytosed by the cells and then fuse with the endosome releasing the BioPORTERcaptured antibody into the cytoplasm. To examine the localization of the transduced antibody, FITC-antibody control protein was mixed with the BioPORTER reagent and added to DCs. After incubation for 4 h, FITC-antibody control protein was mixed with the BioPORTER reagent and added to DCs. After incubation for 4 h, the cells were washed and fixed. Organelles were stained with an anti-Rab5 pAb for early endosomes conjugated with Alexa 594 and visualized with confocal laser microscopy (Fig. 9A) . The results showed that the transduced antibody localized in cytosol but not endosomes, suggesting that the transduced anti-Hsp90 antibody could be expected to bind to both exogenous and endogenous Hsp90 in the cytosol. In fact, the transduced Alexa 594-labeled anti-Hsp90 mAb was co-localized with Alexa 488-labeled exogenous Hsp90 within DCs (data not shown). We next examined whether transduction of the anti-Hsp90 mAb affected the intracellular localization of the exogenous Hsp90-OVA complex in DCs by confocal laser microscopy. We observed that when the anti-Hsp90 mAb was transduced into the cytosol of DCs, co-localization of Hsp90-Alexa 594-OVA complex and Alexa 488-labeled proteasome subunit LMP2 was poorly detected. Although it should be elucidated how the transduced antibody affected the Hsp90 activity, these data suggested that transduction of the anti-Hsp90 antibody resulted in marked inhibition of transportation of Hsp90-chaperoned OVA to the proteasome (Fig. 9B) . In agreement with these data, transduction of the anti-Hsp90 antibody into DCs, but not the control antibody, resulted in partial inhibition of Hsp90-mediated cross-presentation (Fig. 9C) . In contrast, B3Z responses to DCs pulsed with the SL8 peptide with or without antibody transduction were not affected. Since Hsp90-mediated cross-presentation was involved in both the cytosolic and endosomal pathways, this partial inhibition seemed to reflect the inhibition of a cytosolic-proteasome-TAP-dependent pathway, whereas the endosomal pathway might not have been affected. Therefore, we tested whether the transduction of the anti-Hsp90 mAb plus leupeptin treatment of DCs abolished the cross-presentation of the Hsp90-OVA complex. The results showed that these treatments of DCs almost completely inhibited the cross-presentation of Hsp90-OVA (Fig.  9C) . Taking into account the co-localization of exogenous Hsp90, OVA and proteasome subunit LMP-2 shown by the confocal laser study and the results from radicicol treatment, it was suggested that exogenous Hsp90 itself might act as a translocator of chaperoned OVA from early endoosme to cytosol for proteasomal degradation.
Hsp90-OVA complex is cross-presented by DCs in vivo
We examined whether our system worked in vivo. We immunized B6C3F1 mice with the Hsp90-OVA complex or OVA alone and evaluated the appearance of CD11c + DCs that could stimulate B3Z and KZO in the draining lymph nodes. Figure 10A and B show that CD11c + DCs from mice immunized with Hsp90-OVA elicited strong B3Z responses, whereas they did not cause KZO responses. In contrast, CD11c
+ DCs from mice immunized with OVA alone activated KZO, whereas stimulation of B3Z by them led to very weak responses compared with mice immunized with the Hsp90-OVA complex. These results were in agreement with previous findings shown in Fig. 4 that Hsp90-OVA was presented selectively and efficiently through the MHC class I pathway in vitro.
Hsp90-OVA complex elicits OVA-specific CTLs in vivo and protects mice from challenge with tumor cells expressing the OVA protein
We tested whether mice immunized with Hsp90-OVA developed OVA-specific CTL responses. C57BL/6 mice were immunized s.c. on days 0 and 7 with the Hsp90 (20 lg)-OVA (20 lg) complex in the absence of an adjuvant. As shown in Fig. 10C , immunization with Hsp90-OVA induced a strong and OVA-specific CTL response. Then, to study the efficacy of Hsp90-OVA to protect mice against grafted E.G7 tumor cells, mice (n = 10) were injected s.c. on days 0 and 7 with Hsp90 (20 lg)-OVA (20 lg), Hsp90 (20 lg), OVA (20 lg) or PBS, and 7 days after the second immunization, they were grafted i.d. with 10 5 E.G7 cells. All mice immunized with ) or SL8 (1 lM) for 1 h, and fixed, washed and cultured overnight with B3Z. The B3Z response was measured by the absorbance at 595 nm. (B) DCs were pre-incubated with radicicol at 5 lM. Two hours after pre-incubation, DCs were incubated at 37°C with Hsp90-Alexa Fluor 594-labeled-OVA complex for 1 h, and then washed and fixed. Organelles were stained with an anti-LMP2 pAb conjugated with Alexa Fluor 488 and visualized with confocal laser microscopy. Co-localization of internalized Hsp90-OVA and LMP2 is indicated with arrows. (C) DCs were pre-incubated with radicicol at the indicated doses. Two hours after pre-incubation, the DCs were pulsed with OVA (200 mg ml À1 ) or SL8 (1 lM) for 1 h, fixed, washed and cultured overnight with B3Z. The B3Z response was measured by the absorbance at 595 nm. (D) Following treatment of DCs with the indicated concentrations of radicicol for 2 h and culture for 24 h, the cell lysate was harvested. Western blotting of the expression of Hsp72 was done using a specific antibody. The ß-actin level was used as a loading control. Data are shown as means 6 SD of three independent experiments. *, p < 0.01.
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Hsp90, OVA or PBS developed tumors, whereas 60% of mice immunized with Hsp90-OVA remained tumor free (Fig.  10D) . These results showed that the Hsp90-antigen peptide complex induced a strong CTL response to the chaperoned peptide and that this response was sufficiently strong to generate anti-tumor effects.
Discussion
Our results have revealed a novel mode of involvement of Hsp90 in antigen presentation by DCs: exogenous Hsp90 preferentially introduces the chaperoned antigen into the MHC class I pathway, resulting in efficient cross-presentation.
Because there is a classical paradigm that extracellular antigens are presented by MHC class II molecules, it seemed significant to find that Hsp90 changed the fate of the associated antigen on antigen presentation. Recent reports demonstrated that Hsp70-and gp96-antigen complex facilitated antigen presentation in association with both MHC class I and class II molecules (13) (14) (15) . Here, we examined whether an Hsp90-protein complex elicited CD4 + T-cell responses through MHC class II presentation as well as CD8
+ T-cell responses and we found that the Hsp90-OVA complex induced preferential CD8 + T-cell responses. Therefore, we further examined how Hsp90 directs the associated OVA to the cross-presentation pathway compared with the intracellular routing of OVA alone using laser confocal microscopy. We found that the Hsp90-OVA complex entered the MHC class I pathway, which is comprised of an endosomal pathway and proteasome-TAP-dependent pathway. In contrast, the soluble OVA was sorted into an endosome-lysosome pathway, which is regarded as a classical MHC class II pathway. Thus, the Hsp90-OVA complex and OVA followed different routes and it is very important to elucidate the role of Hsp90 in cross-presentation for the development of HSP-based cancer vaccines. We assumed that exogenous Hsp90 was taken up by receptor-dependent endocytosis. In fact, the Calderwood group has recently reported that the scavenger receptor expressed by endothelial cells-1 (SREC-1) acts as the Hsp90 receptor for cross-presentation expressed on DCs (16). Lakadamyali et al.(17) have demonstrated that early endosomes are comprised of two distinct populations: a dynamic population that matures rapidly toward the late endosome and lysosome, and a static early endosome that matures much more slowly. Interestingly, Burgdorf et al. (18) have demonstrated that a mannose receptor introduces exogenous OVA specifically into an EEA-1 + , Rab5 + -static early endosomal compartment for subsequent cross-presentation. In contrast, OVA endocytosed by a scavenger receptor did not co-localize with EEA1; instead, it co-localized with LAMP-1 in the lysosome as shown here, leading to presentation in the context of MHC class II molecules. Thus, we expect that Hsp90-specific receptors such as SREC-1 might introduce the Hsp90-OVA complex into the static early endosome for cross-presentation. Therefore, it should be examined whether the Hsp90-OVA complex is localized to the static early endosome after uptake through Hsp90 receptors, including SREC-1. More importantly, it should be clarified whether such Hsp90 receptors for crosspresentation bear the sorting motifs, which are responsible for introducing the Hsp90-OVA complex into the static early endosome. Identification and characterization of Hsp90 receptors have important implications for further understanding the biology of cross-presentation.
In our previous study, we observed that an exogenous Hsp90-'precursor peptide' complex localized to the early endosome but not the ER (12) . Because our published data indicated that the Hsp90-peptide complex was crosspresented by a TAP-independent endosome-recycling pathway and this Hsp90-mediated cross-presentation was lactacystin-insensitive, we did not examine whether the Hsp90-precursor peptide (13mer) complex reached the proteasome. In cross-presentation of the Hsp90-OVA protein complex, we showed that part of the OVA chaperoned by KZO (B) . The B3Z or KZO response was measured by the absorbance at 595 nm. Data are shown as means 6 SD of three independent experiments. *, P < 0.01. (C) C57BL/6 mice were immunized s.c. with Hsp90-OVA, Hsp90 or OVA on days 0 and 7. Seven days after immunization, induction of SL8-specific CTL against E.G7 and EL-4 pulsed with SL8 peptide was measured by a standard 4-h chromium release assay. Cytotoxicity against E.G7 and EL4 loaded with SL8 (SL8 + EL4) showed statistically significant differences compared with EL4 or YAC-1 cells at all effector to target ratios (P < 0.01). Data are presented as means of triplicate samples and are representative of three independent experiments. (D) C57BL/6 mice were injected s.c. on days 0 and 7 with Hsp90-OVA, Hsp90, OVA or PBS. Seven days after the second immunization, mice were challenged i.d. with 1 3 10 5 E.G7 cells. Tumor size was measured in two dimensions twice a week. Then number of mice in which the tumor was rejected is indicated in parentheses. Data are representative of three independent experiments. Mean tumor diameter and survival on day 25 in the group of mice immunized with Hsp90-OVA showed the significant differences as compared with the other groups (P < 0.001 versus all other groups).
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Hsp90 was transported out to cytosol for proteasomal degradation. These differences may reflect the need for proteasomal processing. More specifically, endosomal protease was sufficient to generate the SL8 epitope (8mer) from the precursor peptide, whereas OVA protein underwent both endosomal and proteasomal processing to generate the epitope. Further examination is required to elucidate the precise mechanism for the decision making on the destination of Hsp90-chaperoned antigens.
In addition, HSP-'peptide' complex-mediated cross-presentation has recently been well demonstrated by many groups, including ours. In contrast, there are only a few reports with regard to HSP-'protein' complex-mediated cross-presentation. Subjeck et al. have reported that an Hsp70 family member grp170-tyrosinase protein complex promotes cross-presentation and induces an anti-tumor effect. However, the intracellular route after uptake of the grp170-tyrosinase complex by DCs has not been explored. Thus, the precise mechanism, such as a translocator or a channel responsible for the translocation of the HSP-'antigen protein' complex from endosomes into cytosol for proteasomal degradation remains to be clarified. It has been suggested that, for TAP-dependent cross-presentation, exogenous antigen that translocates across the endosomal membrane to the cytosol is in a relatively unfolded state because membrane pores (;5-8 Å in a diameter) are not large enough for the passage of Hsp90 and OVA (>90 kDa with hydrodynamic radii >30 Å ) (19, 20) . Therefore, mildly acidic pH in the early endosome (pH 6.3) may be required to partially unfold the Hsp90-OVA complex to translocate it across the endosomal membrane and it may be renatured in the cytosol. Moreover, as the Hsp90-OVA complex is expected to be taken up via receptors such as SREC-1, the acidic condition might be necessary to dissociate the Hsp90-OVA complex from such receptors. In addition, Amigorena et al. have demonstrated that high pH (;7) in the phagosomes is required to prevent the excessive degradation of endocytosed antigen by lysosomal proteases for efficient cross-presentation. In line with these observations, we showed that the Hsp90-OVA complex was targeted to the early endosome, whose pH is believed to be relatively high (pH 6.5), leading to translocation of the Hsp90-OVA complex into cytosol without excessive degradation. However, our data using chloroquine suggested that mildly acidic pH (6.5) in the early endosome was required, probably because of the partial unfolding of the Hsp90-OVA complex as well as dissociation from Hsp90 receptors as described above. In our manuscript, we aimed at determining the underlying mechanism for this antigen translocation necessary for cross-presentation. We have observed that (i) the exogenous Hsp90-OVA complex co-localized with proteasome subunit LMP2 and (ii) blocking of interaction of the exogenous Hsp90-OVA complex and proteasomes by the introduction of an anti-Hsp90 antibody using BioPORTER resulted in the inhibition of cross-presentation. Although it was considered that the transduced anti-Hsp90 mAb also bound to endogenous Hsp90 as well as exogenous Hsp90, our data indicated that inhibition of the endogenous Hsp90 by radicicol did not affect the cross-presentation of the exogenous Hsp90-OVA complex. Furthermore, radicicol treatment did not affected the co-localization of the Hsp90-OVA complex and LMP2. Thus, exogenous Hsp90 seems to play an important role in cytoplasmic translocation of the endocytosed Hsp90-antigen complex. It has been shown that cytoplasmic Hsp90 is essential for the translocation of the diphteria toxin catalytic domain (21) , Clostridium botulinum C2 toxin (22) , fibroblast growth factor (FGF)-1 and FGF-2 (23). Thus certain toxins and growth factors depend on Hsp90 for efficient translocation from endosomes to cytosol. Very recently, Ichiyanagi et al. (20) have demonstrated that endogenous Hsp90 plays an essential role in cross-presentation of both exogenous OVA and cell-associated OVA by DCs. In agreement with their data, we showed that cross-presentation of soluble OVA was sensitive to the Hsp90 inhibitor radicicol, indicating that the endogenous Hsp90 might act as a translocator to the proteasome-TAP-dependent cross-presentation pathway for the exogenous antigen. These findings also suggest that endogenous Hsp90, as well as exogenous Hsp90, might help the exogenous Hsp90-OVA complex translocate into cytosol at the cytosolic face for cross-presentation. More importantly, it should be revealed how Hsp90-OVA complex escapes across the endosomal membrane. Experimental evidence supports existence of chaperones and co-chaperones such as Hsp90 and Hsc 73 on the endolysosomal membrane participating in lysosomal proteolytic pathways such as chaperone-mediated autophagy (24, 25) . Moreover, Hsp90 forms multichaperone complex, which is consisted of Hsc73, p23 and Hop (26) . Therefore, it is possible that these cytoplasmic chaperone complex might play an important role in this Hsp90-mediated cross-presentation and that endogenous Hsp90 might help to translocate the exogenous antigen from endosomal compartment to cytosolic proteasome for degradation. More importantly, it has been suggested that Sec61 complex played an important role in the translocation of exogenous antigens to cytosol for proteasomal degradation (27, 28) . Therefore, it should be clarified whether the Hsp90-OVA complex is pumped out to cytosol through Sec61 complex. Furthermore, association of Hsp90 with the 20S proteasome has been shown to influence proteasomal enzymatic activity (29) . Yamano et al. (30) have demonstrated that antigen processing by proteasomes is regulated by Hsp90 and PA28. They showed that up-regulation of Hsp90 and PA28 enhanced the antigen processing of OVA. Given our observation of the association of exogenous Hsp90 and the proteasome, exogenous Hsp90 might regulate proteasomal activity to create antigenic determinants. Together, our data show that TAP-dependent cross-presentation may require exogenous Hsp90 for the delivery of exogenous antigens into the cytosol for proteasomal proteolysis. The Hsp90 appears to represent an attractive candidate for vaccine development due to its ability to target DCs and to induce specific CTL without the need for an adjuvant.
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